GW prices Sativex for MS pain

GW Pharmaceuticals wasted no time preparing to launch its newly-approved Sativex for MS patients. The UK developer says that it will sell the cannabis-based pain therapy for $14 a day. The Wall Street Journal notes that the approval in Britain should also be an encouragement to developers in the country, which have faced some hard times recently. GW spent 11 years developing Sativex and has high hopes for an eventual U.S. approval for cancer pain. Story